Qesophageal cancer is a frequent and deadly disease linked to environmental factors and resulting from multiple genetic abnormalities variously identified in the malignant cells. Alterations of oncogenes as well as of tumour-suppressor genes (Evans, 1993) have been observed in oesophageal tumours (Huang et al., 1992; Jankowski et al., 1992) . A frequent mechanism of alteration is the amplification of an oncogene locus, resulting in the existence of a high number of copies of a key gene and the overproduction of its messenger RNA and protein product (for review see Brison, 1993) . In oesophageal cancer, amplification of several oncogenes has been reported (for review see Yoshida et al., 1993) . Thus, MYC, ERBBI, encoding the epidermal growth factor (EGF) receptor and potential oncogenes from the 1 1q13 chromosomal region can be found amplified in a high proportion of cases (Hollstein et al., 1988; Lu et al., 1988; Tsuda et al., 1989; Kitagawa et al., 1991; Wagata et al., 1991; Jiang et al., 1992; Mori et al., 1992) .
The 1lq13 chromosomal region, which is amplified in a number of carcinomas (for reviews see Gaudray et al., 1992; Brison, 1993) , reafranged in B-cell (Withers et al., 1991; Williams et al., 1993) and parathyroid tumours (Motokura and Arnold, 1993) and altered in multiple endocrine neoplasia type 1 Janson et al., 1991) , contains several growth regulator genes. Among these, the CCNDI gene (also caled PRADI or CYCDJ, and representing the coding unit of the BCL1 locus) encodes a molecule of the cyclin D family (for reviews see Matsushime et al., 1991; Motokura et al., 1991; Xiong et al., 1991; Motokura and Arnold, 1993) , which is thought to play a key role in the amplification . However, amplification of the 1 1q13 region appears to result from, or to generate, complex genomic processes. Thus, in addition to CCNDI/PRADI, potential unidentified oncogenes of three other 1lq13 subregions, either slightly centromeric or telomeric of the cyclin gene (Szepetowski et al., 1991 Brookes et al., 1993; Karlseder et al., 1994) , are susPected to be selected in some of the amplification units. They are close to the DI 1S97, EMS) (Schuuring et al., 1992) and GARP (Ollendorff et al., 1994) loci. Fmally, another poorly understood characteristic of the 1 1q13 amplification, only established so far in breast tumours, is its frequent association with an amplification of the 8pl2 chromosomal region (Tbeillet et al., 1993) .
The role of the FGF3 and FGF4 Endoscopic biopsy specimens were frozen within 15 min of removal and were stored at -80'C before processing. Tumours were classified as squamous cell carcinomas (n =44) and adenocarcinomas (n = 11). The status of p53 and EGFR proteins were determined by immunohistochemistry (Monges et al., 1994) . The mammary carcinoma cell lines MDA-MB.134 and MDA-MB.231, used as controls of chromosomal 1 1q13 amplification (Lafage et al., 1992) , were obtaied through the Amercan Type Culture Collection and grown according to its recommendations.
Molecular probes
The CCNDI probe was a 1.1 kb EcoRI cDNA fragment derived from a human placenta library using a synthetic oligonucleotide probe corresponding to the CCNDI/PRADI gene sequence (Raynaud et al., 1993) and was a gift from P. Gaudray (Nice, France). The ETSJ probe, located at 1 1q23, was used as control for loading in Southern blot experiments. It was a 0.75 kb HindlII fragment from plasmid pHE5.4 (De Taisne et al., 1984) . The FGF4/HST and GARP/D1 1S833E probes, both located at 1 1q13 telomeric of CCND1, were a 0.8 kb EcoRI-SacI genomic fragment (Adelaide et al., 1988) and a 2.4 kb EcoRI genomic fragment respectively. The Gapdh probe used in control of RNA hybridisations was derived from a mouse clone (Galland et al., 1990 ).
DNA and RNA analyses DNA and RNA extractions were performed as follows. The frozen tumour samples were reduced to powder using a Spex 7000 (Bioblock Scientific) in the presence of guanidinium isothyocyanate. The powder was then heated to 50°C for 15 min. The resulting solution was centrifuged for 3 h at 50 000 r.p.m. The RNA was obtained from the pellet, resuspended in distilled water and stored before use. The DNA present in the supernatant was treated as previously described (Theillet et al., 1989) . Southern and Northern blot hybridisations were performed as described by Theillet et al. (1993) . The levels of amplification were quantitatively assessed by densitometry scanning (LKB) by comparison with the control probe and normal tissue. Owing to a possible dilution of the tumoral component by stromal tissue (each sample was derived from several pooled biopsies) a cut-off value of 2-fold was chosen for amplification.
Results
Amplification of CCND1 in human oesophageal tumours The amplification status of the CCNDJ gene was assessed by Southern blot analysis in a panel of 55 DNAs extracted from oesophageal tumour samples. The results are shown in Table  I and examples of Southern blot hybridization are shown in Figure 1 . Twenty-four squamous cell tumours out of 44 (54%) showed amplification of the CCNDJ gene. Compared with normal oesophagus, the number of gene copies was increased between 2 and 12 times. Amplification of at least 3-fold occurred in 45% of the tumours. Amplification was only observed in squamous carcinomas; none of the 11 adenocarcinomas exhibited amplification of CCNDJ (Table  I) . A probe for the ETSJ gene, located at 1 1q23, was used as a control for DNA loading. ETSJ was never amplified. Probes for the FGF4 and GARP genes (Ollendorff et al., 1994) , located at 1 1q13.3 (Adelaide et al., 1988; Hagemeijer et al., 1991) and 11q13.5-q14 (Ollendorff et al., 1992) respectively, were used to estimate the size and structure of the amplification units (Figure 1 ). FGF4 was amplified in 11 cases out of 42 tested (26%). All cases showed amplification of CCNDJ. GARP was amplified in 10 cases out of 42 (23.7%). In three of these cases, CCNDJ was not amplified. Thus, there does not seem to exist fundamental qualitative differences between lq13 amplifications in oesophageal and Figure 2 ) expressed CCND1 at a significant level, and all amplified tumours overexpressed CCNDJ but two
amplified tumours could not be tested for expression (see details in Table II ).
breast cancers since co-amplification of FGF4 with CCNDJ and independent amplification of GARP are observed (Karlseder et al., 1994) but the overall frequency of amplification is higher. (Hunter and Pines, 1991; Motokura and Arnold, 1993) . This is based on several observations, in particular: (i) the localisation of CCNDI in the major core of the amplified region (Karlseder et al., 1994) ; (ii) a good correlation between expression and amplification of CCNDI in tumours with an 1 IqI3-amplified region ; (iii) the consistent expression of CCNDI in lymphomas with a t(I 1;14) translocation (Rosenberg et al., 1991; Withers et al., 1991) ; and (iv) the capacity for CCNDI to be activated by tumoral rearrangements (reviewed in Motokura and Arnold, 1993) . Furthermore, cycin D2 and cycin E genes have been found to be amplified in some human tumours (Buckley et al., 1993; Keyomarsi and Pardee, 1993; Leach et al., 1993) , and cyclin A can be activated by provirus insertion in liver cancer (Wang et al., 1990) . Finally, even in the absence of amplification or trans- (Buckley et al., 1993; Keyomarsi and Pardee, 1993) . The present report strengthens these observations. It illustrates the possible involvement of CCNDI in squamous cell carcinomas of the oesophagus. The incidence of amplification and overexpression of CCNDI in this type of tumour is high, between 45 and 54% depending on the threshold retained for a bona fide amplification. This was expected since it had ahready been observed that amplification of the chromosomal region where CCNDI is located is especially frequent in this type of cancer (Tsuda et al., 1989; Kitagawa et al., 1991; Wagata et al., 1991) . The proportion of oesophageal tumours amplified for probes of the 1 1q13 region varies from 24% (Mori et al., 1992) to 52% (Tsuda et al., 1989) . The lowest incidence, found with an FGF3 probe, is close to what we observed using FGF4 as a probe. Mori et al. (1992) observed an association between CCNDI amplification and we were unable to confirm this, although the trend in our data is in a similar direction. At any rate, although almost two-thirds of the squamous cell carcinomas overexpress CCNDJ, any effect on the survival of the patients is seen only after 12 months. Whether this reflects the initial presence of involved lymph nodes or a enhanced aggression of the carcinoma cells themselves remains unclear at the present time. The exact role of CCNDI should be discussed with respect to the general complexity of the amplification process. Amplified units can be large and can contain several categories of genes. In addition to amplified but not overexpressed 'silent passenger' genes and 'unwanted passengers', which may have a negative effect on cell proliferation or on the maintenance of the amplification and which are eliminated, at least one pathologically relevant oncogene is assumed to be present in an amplification unit. It corresponds to the selected key 'driver' gene. In certain cases more than one gene may be selected to create independent amplicons within the same large region Karlseder et al., 1994) . CCNDI seems to be a key gene of the 1 1q13 amplification, and the data reported here, showing a good correlation between amplification and expression, strengthen this hypothesis. However, another category of genes is the 'opportunistic passenger' genes. They are present in the amplification unit but are not primarily selected and responsible for the amplification. They become deregulated and are overexpressed as a consequence of the elevated gene copies number. CCNDI may also belong to this category, although evidence is mounting that it actually represents a key oncogene (see Motokura and Arnold, for a review).
In the cases with overexpression without increased gene copy number, it is possible that the method of Southern blotting used is not sensitive enough. This question could be solved by using other methods, such as fluorescence in situ hybridisation on chromosomes (Kallioniemi et al., 1992) . Alternatively, in the adenocarcinomas, it may result from a mechanism of regulation which is intrinsically different from the squamous subtype.
Cyclins and other components of the cell cycle, together with regulators of genome integrity and cell survival (Hunter, 1993; Lanfrancone et al., 1994) , represent 'cancer genes' which may be as relevant to tumour development as the so-called classical oncogenes. The analysis of their involvement in human cancer is of primary importance. Thus, the possible role of other cyclins and cell cycle components in oesophageal tumours should continue to be analysed. The association with possible amplification of other chromosomal regions should also be investigated.
